Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain with intent to treat or currently treated with opioids. Exclusion criteria will include current cannabis use, severe medical illness or lacking in capacity to be involved in study. TC and TP will be prescribed for use TID in predefined dosages and quantities.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Louisiana State University Health Sciences Center Shreveport
• Treatments: Cannabidiol; Epidiolex

Criteria

Inclusion Criteria

1. Diagnosis of chronic musculoskeletal joint pain (arthritis, traumatic arthritis, osteoarthritis)

2. Adults ages 18 and over.

3. Medically stable without significant medical illness that would preclude treatment with either pharmacologic agent.

4. Have a safe, stable, living environment.

Exclusion Criteria

1. Unable to consent for research project.

2. Individuals less than 18 years of age.

3. Individuals with rheumatoid or other autoimmune types of arthritis.

4. Individuals diagnosed with SUD especially cannabis, as this may confound results.